Summary of findings 3. FLUPENTHIXOL DECANOATE HIGH DOSE compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) for schizophrenia or other similar psychotic disorders.
| FLUPENTHIXOL DECANOATE HIGH DOSE compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) for schizophrenia or other similar psychotic disorders | ||||||
| Patient or population: patients with schizophrenia or other similar psychotic disorders Settings: inpatient Intervention: FLUPENTHIXOL DECANOATE HIGH DOSE Comparison: FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) | FLUPENTHIXOL DECANOATE HIGH DOSE | |||||
| Clinical response: mental state ‐ relapse ‐ medium term Relapse rate Follow‐up: 44 weeks | 333 per 10001 | 333 per 1000 (90 to 1000) | RR 1 (0.27 to 3.69) | 18 (1 study) | ⊕⊕⊝⊝ low2 | |
| Clinical response: mental state ‐ general score ‐ medium term Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 126. Follow‐up: 44 weeks | The mean clinical response: mental state ‐ general score ‐ medium term in the control groups was 26.44 points | The mean clinical response: mental state ‐ general score ‐ medium term in the intervention groups was 10.44 lower (18.7 to 2.18 lower) | 18 (1 study) | ⊕⊕⊝⊝ low3,4 | ||
| Clinical response: global state ‐ no clinical improvement ‐ short/medium term ‐ not reported | See comment | See comment | Not estimable | ‐ | See comment | No study reported this outcome. |
| Service utilisation: hospital admission ‐ medium/long term ‐ not reported | See comment | See comment | Not estimable | ‐ | See comment | No study reported this outcome. |
| Leaving the study early ‐ short/medium term Rate of attrition Follow‐up: mean 26 weeks | Low4 | RR 0.16 (0.03 to 0.82) | 42 (2 studies) | ⊕⊕⊝⊝ low2,3 | ||
| 200 per 1000 | 32 per 1000 (6 to 164) | |||||
| Moderate4 | ||||||
| 400 per 1000 | 64 per 1000 (12 to 328) | |||||
| High4 | ||||||
| 600 per 1000 | 96 per 1000 (18 to 492) | |||||
| Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term numbers requiring anticholinergic medication Follow‐up: mean 10.5 weeks | See comment | See comment | Not estimable | 47 (2 studies) | ⊕⊝⊝⊝ very low2,3 | Data not pooled for summary of findings table due to substantial heterogeneity. |
| Economic outcomes ‐ long term ‐ not reported | See comment | See comment | Not estimable | ‐ | See comment | No study reported this outcome. |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Assumed risk: mean baseline risk from single study. 2 Imprecision: rated 'serious' ‐ confidence intervals for best estimate of effect include both 'no effect' and appreciable benefit/harm; high degrees of heterogeneity (I2 = 59%). 3 Risk of bias: rated 'serious' ‐ no mention of randomisation procedure; unreported outcomes of interest; involvement by pharmaceutical company. 4 Assumed risk: 'moderate' equates to that of control group. Low, moderate and high risks calculated from included studies.